NCT06666634CompletedPhase 2
Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
99mTc-nanocolloid, the world wide used hybrid tracer for dynamic sentinel node biopsy, has recently been replaced with 99mTc-nanoscan. The hybrid form (ICG-99mTc-nanoscan) has not yet been validated, to show the similarity between the lymphatic drainage pattern between ICG-99mTc-nanoscan and 99mTc-nanoscan.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- First submitted
- 1 Mar 2023
- Start date
- 1 Apr 2023
- Primary completion date
- 14 Jul 2025
- Lead sponsor
- The Netherlands Cancer Institute
- Diseases
- Melanoma
- NCT number
- NCT06666634
- EU CT number
- 2024-519351-28-00
- EudraCT number
- 2022-003297-24
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 29
- From 1 Apr 2023 to the primary completion date, 14 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with known allergy to patent blue dye or nanocolloid;
- History of iodine allergy
- Kidney insufficiency
Lab values
- History of hypersensitivity reactions to products containing human serum albumin;
Other
- Patients who are pregnant or breast-feeding mothers;
- Hyperthyroid or thyroidal adenoma
- Incapacity or unwillingness of participant to give written informed consent;
Who the study is looking for
- Patient who will undergo a sentinel node procedure in routine care.
- Patients > 18 years;
- Patients presenting with:
- a primary cutaneous melanoma of head/neck or upper part of the trunk or extremities;
- OR patients presenting with a primary oral cavity malignancy T1-2N0
- OR patients with primary penile cancer
- Patients with clinical N0 stage;
- Patients scheduled for a sentinel node biopsy prior to (re-)excision of the primary lesion;
- Patients in which ICG-99mTc-nanoscan would be used in routine care or a research setting
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.